Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Tegally, H.; San, J. E.; Cotten, M.; Moir, M.; Tegomoh, B.; Mboowa, G.; Martin, D. P.; Baxter, C.; Lambisia, A. W.; Diallo, A.; Amoako, D. G.; Diagne, M. M.; Sisay, A.; Zekri, A. N.; Gueye, A. S.; Sangare, A. K.; Ouedraogo, A. S.; Sow, A.; Musa, A. O.; Sesay, A. K.; Abias, A. G.; Elzagheid, A. I.; Lagare, A.; Kemi, A. S.; Abar, A. E.; Johnson, A. A.; Fowotade, A.; Oluwapelumi, A. O.; Amuri, A. A.; Juru, A.; Kandeil, A.; Mostafa, A.; Rebai, A.; Sayed, A.; Kazeem, A.; Balde, A.; Christoffels, A.; Trotter, A. J.; Campbell, A.; Keita, A. K.; Kone, A.; Bouzid, A.; Souissi, A.; Agweyu, A.; Naguib, A.; Gutierrez, A. V.; Nkeshimana, A.; Page, A. J.; Yadouleton, A.; Vinze, A.; Happi, A. N.; Chouikha, A.; Iranzadeh, A.; Maharaj, A.; Batchi-Bouyou, A. L.; Ismail, A.; Sylverken, A. A.; Goba, A.; Femi, A.; Sijuwola, A. E.; Marycelin, B.; Salako, B. L.; Oderinde, B. S.; Bolajoko, B.; Diarra, B.; Herring, B. L.; Tsofa, B.; Lekana-Douki, B.; Mvula, B.; Njanpop-Lafourcade, B. M.; Marondera, B. T.; Khaireh, B. A.; Kouriba, B.; Adu, B.; Pool, B.; McInnis, B.; Brook, C.; Williamson, C.; Nduwimana, C.; Anscombe, C.; Pratt, C. B.; Scheepers, C.; Akoua-Koffi, C. G.; Agoti, C. N.; Mapanguy, C. M.; Loucoubar, C.; Onwuamah, C. K.; Ihekweazu, C.; Malaka, C. N.; Peyrefitte, C.; Grace, C.; Omoruyi, C. E.; Rafaï, C. D.; Morang'a, C. M.; Erameh, C.; Lule, D. B.; Bridges, D. J.; Mukadi-Bamuleka, D.; Park, D.; Rasmussen, D. A.; Baker, D.; Nokes, D. J.; Ssemwanga, D.; Tshiabuila, D.; Amuzu, D. S. Y.; Goedhals, D.; Grant, D. S.; Omuoyo, D. O.; Maruapula, D.; Wanjohi, D. W.; Foster-Nyarko, E.; Lusamaki, E. K.; Simulundu, E.; Ong'era, E. M.; Ngabana, E. N.; Abworo, E. O.; Otieno, E.; Shumba, E.; Barasa, E.; Ahmed, E. B.; Ahmed, E. A.; Lokilo, E.; Mukantwari, E.; Philomena, E.; Belarbi, E.; Simon-Loriere, E.; Anoh, E. A.; Manuel, E.; Leendertz, F.; Taweh, F. M.; Wasfi, F.; Abdelmoula, F.; Takawira, F. T.; Derrar, F.; Ajogbasile, F. V.; Treurnicht, F.; Onikepe, F.; Ntoumi, F.; Muyembe, F. M.; Ragomzingba, F. E. Z.; Dratibi, F. A.; Iyanu, F. A.; Mbunsu, G. K.; Thilliez, G.; Kay, G. L.; Akpede, G. O.; van Zyl, G. U.; Awandare, G. A.; Kpeli, G. S.; Schubert, G.; Maphalala, G. P.; Ranaivoson, H. C.; Omunakwe, H. E.; Onywera, H.; Abe, H.; Karray, H.; Nansumba, H.; Triki, H.; Kadjo, H. A. A.; Elgahzaly, H.; Gumbo, H.; Mathieu, H.; Kavunga-Membo, H.; Smeti, I.; Olawoye, I. B.; Adetifa, I. M. O.; Odia, I.; Ben Boubaker, I. B.; Mohammad, I. A.; Ssewanyana, I.; Wurie, I.; Konstantinus, I. S.; Halatoko, J. W. A.; Ayei, J.; Sonoo, J.; Makangara, J. C.; Tamfum, J. M.; Heraud, J. M.; Shaffer, J. G.; Giandhari, J.; Musyoki, J.; Nkurunziza, J.; Uwanibe, J. N.; Bhiman, J. N.; Yasuda, J.; Morais, J.; Kiconco, J.; Sandi, J. D.; Huddleston, J.; Odoom, J. K.; Morobe, J. M.; Gyapong, J. O.; Kayiwa, J. T.; Okolie, J. C.; Xavier, J. S.; Gyamfi, J.; Wamala, J. F.; Bonney, J. H. K.; Nyandwi, J.; Everatt, J.; Nakaseegu, J.; Ngoi, J. M.; Namulondo, J.; Oguzie, J. U.; Andeko, J. C.; Lutwama, J. J.; Mogga, J. J. H.; O'Grady, J.; Siddle, K. J.; Victoir, K.; Adeyemi, K. T.; Tumedi, K. A.; Carvalho, K. S.; Mohammed, K. S.; Dellagi, K.; Musonda, K. G.; Duedu, K. O.; Fki-Berrajah, L.; Singh, L.; Kepler, L. M.; Biscornet, L.; de Oliveira Martins, L.; Chabuka, L.; Olubayo, L.; Ojok, L. D.; Deng, L. L.; Ochola-Oyier, L. I.; Tyers, L.; Mine, M.; Ramuth, M.; Mastouri, M.; ElHefnawi, M.; Mbanne, M.; Matsheka, M. I.; Kebabonye, M.; Diop, M.; Momoh, M.; Lima Mendonça, M. D. L.; Venter, M.; Paye, M. F.; Faye, M.; Nyaga, M. M.; Mareka, M.; Damaris, M. M.; Mburu, M. W.; Mpina, M. G.; Owusu, M.; Wiley, M. R.; Tatfeng, M. Y.; Ayekaba, M. O.; Abouelhoda, M.; Beloufa, M. A.; Seadawy, M. G.; Khalifa, M. K.; Matobo, M. M.; Kane, M.; Salou, M.; Mbulawa, M. B.; Mwenda, M.; Allam, M.; Phan, M. V. T.; Abid, N.; Rujeni, N.; Abuzaid, N.; Ismael, N.; Elguindy, N.; Top, N. M.; Dia, N.; Mabunda, N.; Hsiao, N. Y.; Silochi, N. B.; Francisco, N. M.; Saasa, N.; Bbosa, N.; Murunga, N.; Gumede, N.; Wolter, N.; Sitharam, N.; Ndodo, N.; Ajayi, N. A.; Tordo, N.; Mbhele, N.; Razanajatovo, N. H.; Iguosadolo, N.; Mba, N.; Kingsley, O. C.; Sylvanus, O.; Femi, O.; Adewumi, O. M.; Testimony, O.; Ogunsanya, O. A.; Fakayode, O.; Ogah, O. E.; Oludayo, O. E.; Faye, O.; Smith-Lawrence, P.; Ondoa, P.; Combe, P.; Nabisubi, P.; Semanda, P.; Oluniyi, P. E.; Arnaldo, P.; Quashie, P. K.; Okokhere, P. O.; Bejon, P.; Dussart, P.; Bester, P. A.; Mbala, P. K.; Kaleebu, P.; Abechi, P.; El-Shesheny, R.; Joseph, R.; Aziz, R. K.; Essomba, R. G.; Ayivor-Djanie, R.; Njouom, R.; Phillips, R. O.; Gorman, R.; Kingsley, R. A.; Neto Rodrigues, Rmdesa, Audu, R. A.; Carr, R. A. A.; Gargouri, S.; Masmoudi, S.; Bootsma, S.; Sankhe, S.; Mohamed, S. I.; Femi, S.; Mhalla, S.; Hosch, S.; Kassim, S. K.; Metha, S.; Trabelsi, S.; Agwa, S. H.; Mwangi, S. W.; Doumbia, S.; Makiala-Mandanda, S.; Aryeetey, S.; Ahmed, S. S.; Ahmed, S. M.; Elhamoumi, S.; Moyo, S.; Lutucuta, S.; Gaseitsiwe, S.; Jalloh, S.; Andriamandimby, S. F.; Oguntope, S.; Grayo, S.; Lekana-Douki, S.; Prosolek, S.; Ouangraoua, S.; van Wyk, S.; Schaffner, S. F.; Kanyerezi, S.; Ahuka-Mundeke, S.; Rudder, S.; Pillay, S.; Nabadda, S.; Behillil, S.; Budiaki, S. L.; van der Werf, S.; Mashe, T.; Mohale, T.; Le-Viet, T.; Velavan, T. P.; Schindler, T.; Maponga, T. G.; Bedford, T.; Anyaneji, U. J.; Chinedu, U.; Ramphal, U.; George, U. E.; Enouf, V.; Nene, V.; Gorova, V.; Roshdy, W. H.; Karim, W. A.; Ampofo, W. K.; Preiser, W.; Choga, W. T.; Ahmed, Y. A.; Ramphal, Y.; Bediako, Y.; Naidoo, Y.; Butera, Y.; de Laurent, Z. R.; Ouma, A. E. O.; von Gottberg, A.; Githinji, G.; Moeti, M.; Tomori, O.; Sabeti, P. C.; Sall, A. A.; Oyola, S. O.; Tebeje, Y. K.; Tessema, S. K.; de Oliveira, T.; Happi, C.; Lessells, R.; Nkengasong, J.; Wilkinson, E..
Science ; : eabq5358, 2022.
Article in English | PubMed | ID: covidwho-2029459

ABSTRACT

Investment in SARS-CoV-2 sequencing in Africa over the past year has led to a major increase in the number of sequences generated, now exceeding 100,000 genomes, used to track the pandemic on the continent. Our results show an increase in the number of African countries able to sequence domestically, and highlight that local sequencing enables faster turnaround time and more regular routine surveillance. Despite limitations of low testing proportions, findings from this genomic surveillance study underscore the heterogeneous nature of the pandemic and shed light on the distinct dispersal dynamics of Variants of Concern, particularly Alpha, Beta, Delta, and Omicron, on the continent. Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve, while the continent faces many emerging and re-emerging infectious disease threats. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century.

2.
Journal of Infectious Diseases ; 26:26, 2022.
Article in English | MEDLINE | ID: covidwho-2017957

ABSTRACT

This study was one of the first to detect Omicron sublineages BA.4 and BA.5 in wastewater from South Africa. Spearman rank correlation analysis confirmed a strong positive correlation exists between SARS-CoV-2 viral RNA in wastewater samples and clinical cases (r = 0.7749, p < 0.0001). SARS-CoV-2 viral load detected in wastewater, resulting from the Delta-driven 3rd wave, was significantly higher than during the Omicron-driven 4th wave, p < 0.005. Whole-genome sequencing confirmed the presence of Omicron lineage defining mutations in wastewater with the first occurrence reported on 23 November 2021 (BA.1 predominant). The variant rapidly spread, with the prevalence of Omicron positive wastewater samples rising to >80% by 10 January 2022 with BA.2 as the predominant sub-lineage by 10 March 2022, whilst on 18 April 2022 BA.4 and BA.5 were detected in selected wastewater sites. Taken together, these findings demonstrate the value of WBE to monitor the spatiotemporal spread and potential origination of new Omicron sub-lineages of SARS-CoV-2.

3.
South African Medical Journal ; 112(3):192-193, 2022.
Article in English | EMBASE | ID: covidwho-1761103
4.
Embase;
Preprint in English | EMBASE | ID: ppcovidwho-326897

ABSTRACT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in southern Africa has been characterised by three distinct waves. The first was associated with a mix of SARS-CoV-2 lineages, whilst the second and third waves were driven by the Beta and Delta variants respectively1–3. In November 2021, genomic surveillance teams in South Africa and Botswana detected a new SARS-CoV-2 variant associated with a rapid resurgence of infections in Gauteng Province, South Africa. Within three days of the first genome being uploaded, it was designated a variant of concern (Omicron) by the World Health Organization and, within three weeks, had been identified in 87 countries. The Omicron variant is exceptional for carrying over 30 mutations in the spike glycoprotein, predicted to influence antibody neutralization and spike function4. Here, we describe the genomic profile and early transmission dynamics of Omicron, highlighting the rapid spread in regions with high levels of population immunity.

5.
Afr J Thorac Crit Care Med ; 27(4)2021.
Article in English | MEDLINE | ID: covidwho-1502738

ABSTRACT

SUMMARY: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is transmitted mainly by aerosol in particles <10 µm that can remain suspended for hours before being inhaled. Because particulate filtering facepiece respirators ('respirators'; e.g. N95 masks) are more effective than surgical masks against bio-aerosols, many international organisations now recommend that health workers (HWs) wear a respirator when caring for individuals who may have COVID-19. In South Africa (SA), however, surgical masks are still recommended for the routine care of individuals with possible or confirmed COVID-19, with respirators reserved for so-called aerosol-generating procedures. In contrast, SA guidelines do recommend respirators for routine care of individuals with possible or confirmed tuberculosis (TB), which is also transmitted via aerosol. In health facilities in SA, distinguishing between TB and COVID-19 is challenging without examination and investigation, both of which may expose HWs to potentially infectious individuals. Symptom-based triage has limited utility in defining risk. Indeed, significant proportions of individuals with COVID-19 and/or pulmonary TB may not have symptoms and/or test negative. The prevalence of undiagnosed respiratory disease is therefore likely significant in many general clinical areas (e.g. waiting areas). Moreover, a proportion of HWs are HIV-positive and are at increased risk of severe COVID-19 and death. RECOMMENDATIONS: Sustained improvements in infection prevention and control (IPC) require reorganisation of systems to prioritise HW and patient safety. While this will take time, it is unacceptable to leave HWs exposed until such changes are made. We propose that the SA health system adopts a target of 'zero harm', aiming to eliminate transmission of respiratory pathogens to all individuals in every healthcare setting. Accordingly, we recommend: the use of respirators by all staff (clinical and non-clinical) during activities that involve contact or sharing air in indoor spaces with individuals who: (i) have not yet been clinically evaluated; or (ii) are thought or known to have TB and/or COVID-19 or other potentially harmful respiratory infections;the use of respirators that meet national and international manufacturing standards;evaluation of all respirators, at the least, by qualitative fit testing; andthe use of respirators as part of a 'package of care' in line with international IPC recommendations. We recognise that this will be challenging, not least due to global and national shortages of personal protective equipment (PPE). SA national policy around respiratory protective equipment enables a robust framework for manufacture and quality control and has been supported by local manufacturers and the Department of Trade, Industry and Competition. Respirator manufacturers should explore adaptations to improve comfort and reduce barriers to communication. Structural changes are needed urgently to improve the safety of health facilities: persistent advocacy and research around potential systems change remain essential.

6.
PLoS ONE ; 16(2), 2021.
Article in English | CAB Abstracts | ID: covidwho-1410704

ABSTRACT

Background: Inequality is rife throughout South Africa. The first wave of COVID-19 may have affected people in lower socioeconomic groups worse than the affluent. The SARS-CoV-2 seroprevalence and the specificity of anti-SARS-CoV-2 antibody tests in South Africa is not known.

7.
Afr J Thorac Crit Care Med ; 26(2)2020.
Article in English | MEDLINE | ID: covidwho-1304841

ABSTRACT

Coronavirus disease 2019 (COVID-19) due to a novel virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic that has resulted in over 1.5 million confirmed cases and close to 100 000 deaths. In the majority of symptomatic cases, COVID-19 results in a mild disease predominantly characterised by upper respiratory tract symptoms. Reverse transcription polymerase chain reaction (RT-PCR) using a nasopharyngeal sample is the mainstay of diagnosis, but there is an ~30% false negative rate early in the disease and in patients with mild disease, and therefore repeat testing may be required. RT-PCR positivity can persist for several days after resolution of symptoms. IgM and IgG antibody responses become positive several days after the onset of symptoms, and robust antibody responses are detectable in the second week of illness. Antibody-based immunoassays have a limited role in the diagnosis of early symptomatic disease. However, their incremental benefit over RT-PCR in the first 2 weeks of illness is currently being clarified in ongoing studies. Such assays may be useful for surveillance purposes. However, their role in potentially selecting individuals who may benefit from vaccination, or as a biomarker identifying persons who could be redeployed into essential employment roles, is being investigated. Rapid antibody-based immunoassays that detect viral antigen in nasopharyngeal samples are being developed and evaluated.

8.
Africa Health ; 42(3):26-29, 2020.
Article in English | GIM | ID: covidwho-1124200

ABSTRACT

Virologists working in large diagnostic laboratories in South Africa give insights into testing in a pandemic. As the Covid-19 pandemic unfolds, several factors have come to the fore as particularly relevant. Rather than give an overview of current testing guidelines and practices which are prone to change over time, and in any case, for which good reviews are available, the study instead wants to list some of the pertinent issues encountered in South Africa, the African country first and so far worst hit by the pandemic, and some proposed solutions. Clear and up-to-date guidance is needed and must be followed by all role players, including different spheres of government. In South Africa for example, some official governmental recommendations have not been aligned with national Department of Health guidance, and for example, required negative PCR test results before an individual who had Covid-19 was allowed back to their workplace. Such unnecessary requirements serve no purpose but increase the burden on laboratories and interfere with testing of clinically and epidemiologically relevant samples. As the SARS-CoV-2 pandemic spreads, laboratory staff will become infected, too;their infection risk is not exposure to specimens (provided some simple precautions are being followed) but instead to the community and also colleagues. Therefore, the same rules will have to be followed as in all workplaces, including universal wearing of non-medical (cloth) masks, physical distancing, improved hand hygiene, regular cleaning and disinfection of surfaces, etc.

9.
Frontiers in Ecology and Evolution ; 9, 2021.
Article in English | Scopus | ID: covidwho-1106022

ABSTRACT

Existing collaborations among public health practitioners, veterinarians, and ecologists do not sufficiently consider illegal wildlife trade in their surveillance, biosafety, and security (SB&S) efforts even though the risks to health and biodiversity from these threats are significant. We highlight multiple cases to illustrate the risks posed by existing gaps in understanding the intersectionality of the illegal wildlife trade and zoonotic disease transmission. We argue for more integrative science in support of decision-making using the One Health approach. Opportunities abound to apply transdisciplinary science to sustainable wildlife trade policy and programming, such as combining on-the-ground monitoring of health, environmental, and social conditions with an understanding of the operational and spatial dynamics of illicit wildlife trade. We advocate for (1) a surveillance sample management system for enhanced diagnostic efficiency in collaboration with diverse and local partners that can help establish new or link existing surveillance networks, outbreak analysis, and risk mitigation strategies;(2) novel analytical tools and decision support models that can enhance self-directed local livelihoods by addressing monitoring, detection, prevention, interdiction, and remediation;(3) enhanced capacity to promote joint SB&S efforts that can encourage improved human and animal health, timely reporting, emerging disease detection, and outbreak response;and, (4) enhanced monitoring of illicit wildlife trade and supply chains across the heterogeneous context within which they occur. By integrating more diverse scientific disciplines, and their respective scientists with indigenous people and local community insight and risk assessment data, we can help promote a more sustainable and equitable wildlife trade. © Copyright © 2021 Aguirre, Gore, Kammer-Kerwick, Curtin, Heyns, Preiser and Shelley.

10.
South African Journal of Science ; 116(9-10), 2020.
Article in English | Scopus | ID: covidwho-921320
11.
Encyclopedia of Environmental Health ; 2020.
Article in English | PMC | ID: covidwho-848642

ABSTRACT

Severe acute respiratory syndrome (SARS) emerged in southern China in late 2002. It first spread within Guangdong Province and then to other parts of China. Via air travelers, it quickly reached various countries around the globe, causing several major hospital outbreaks.Within weeks, the causative agent, a previously unknown coronavirus (SARS-CoV), was identified, thanks to an unprecedented international effort led by the World Health Organization (WHO). Its origin was quickly traced to wild animals traded locally for culinary purposes. Masked palm civet and some other species seem to have acted as intermediate hosts. Since then, SARS-like coronaviruses were found in different bat species in China and elsewhere, and bats are now regarded as the wildlife reservoir for SARS-CoV.Fortunately, the SARS outbreak could be contained within months. Until July 2003, it had caused 8096 cases, with 774 deaths. Once adequate measures such as isolating patients and quarantining their contacts were strictly adhered to, further transmission between human beings could be interrupted.SARS is an example of how rapidly an infectious agent can spread in the modern world. At the same time, it should serve as a showcase of how international cooperation and modern science can help to combat the spread of infectious diseases. FAU - Berger, A.

12.
S Afr Med J ; 110(9): 842-845, 2020 07 17.
Article in English | MEDLINE | ID: covidwho-743542

ABSTRACT

Antibody tests for the novel coronavirus, SARS-CoV2, have been developed both as rapid diagnostic assays and for high-throughput formal serology platforms. Although these tests may be a useful adjunct to a diagnostic strategy, they have a number of limitations. Because of the antibody and viral dynamics of the coronavirus, their sensitivity can be variable, especially at early time points after symptom onset. Additional data are required on the performance of the tests in the South African population, especially with regard to development and persistence of antibody responses and whether antibodies are protective against reinfection. These tests may, however, be useful in guiding the public health response, providing data for research (including seroprevalence surveys and vaccine initiatives) and development of therapeutic strategies.


Subject(s)
Betacoronavirus , Clinical Laboratory Techniques , Coronavirus Infections , Immunologic Tests/methods , Pandemics , Pneumonia, Viral , Serologic Tests/methods , Betacoronavirus/genetics , Betacoronavirus/immunology , Betacoronavirus/isolation & purification , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques/methods , Clinical Laboratory Techniques/standards , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Coronavirus Infections/immunology , Humans , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/immunology , Reproducibility of Results , SARS-CoV-2 , Sensitivity and Specificity , Seroepidemiologic Studies , South Africa/epidemiology
13.
Public Health ; 185: 60, 2020 08.
Article in English | MEDLINE | ID: covidwho-616936
SELECTION OF CITATIONS
SEARCH DETAIL